Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2026)

Royalty Pharma (RPRX) has 7 years of Accumulated Expenses data on file, last reported at $25.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 31.64% year-over-year to $25.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.3 million (up 31.64% YoY), and the FY2025 full-year result was $110.8 million, up 13.01% from the prior year.
• Accumulated Expenses slipped to $25.3 million in Q1 2026, from $110.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $110.8 million in Q4 2025 to a low of $12.6 million in Q3 2023.
• A 5-year average of $43.6 million and a median of $38.4 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 204.98% in 2024 and retreated 24.39% in 2025, its largest moves.
• Tracing RPRX's Accumulated Expenses over 5 years: stood at $54.2 million in 2022, then dropped by 4.58% to $51.7 million in 2023, then surged by 89.74% to $98.1 million in 2024, then advanced by 13.01% to $110.8 million in 2025, then plunged by 77.17% to $25.3 million in 2026.
• Business Quant data shows RPRX's Accumulated Expenses at $25.3 million in Q1 2026, $110.8 million in Q4 2025, and $29.0 million in Q3 2025.